Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy

Bayer

Status: Completed

Conditions: Contraception

Treatments: Drug: EV/DNG (Qlaira, BAY86-5027)

Study type: Observational

Funder types: Industry

Identifiers

NCT01602770

QL1210MX (Other Identifier)

16233

Details and patient eligibility

About

Qlaira is a combined oral contraceptive (COC) containing dienogest/estradiol valerate being the first oral contraceptive delivering estradiol. It has been recently approved in Mexico. To evaluate the clinical profile of this drug combination under routine medical condition, a post-authorization safety study required by Mexican Health Authorities will be conducted in Mexican women.

The study will be performed as a descriptive study, no hypothesis will be tested. The cohort consists of 300 new users (first-ever users or switchers) of Qlaira under routine medical conditions. Subjects should provide all necessary information on health-related events or changes in health status during Qlaira use.

Primary variable will be the incidence of Adverse Events (AE) at any time point, whether or not related to Qlaira during at least 2 years of observation.

In order to comply with the criteria of a non-interventional study, women only will be informed about the study, asked to participate and included in the study after Qlaira has been prescribed.

Study patients follow-up will be done in accordance with common clinical practice as described at Mexican Official Guidelines for prescription of Family Planning Methods (NOM 005-SSA2-1993).

Enrollment: 1 patient

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Healthy women of reproductive age who are:

• Seeking fertility control with oral contraception at least for one year
• Able to go back to medical office on regular basis

Exclusion criteria

Women with risk parameters of arterial or venous thrombotic diseases such as:

• Smoke, if over age 35
• Deep vein thrombosis or pulmonary embolism, now or in the past
• Cerebrovascular disease
• Coronary artery disease
• Thrombogenic valvular or thrombogenic rhythm diseases of the heart
• Inherited or acquired hypercoagulopathies
• Uncontrolled hypertension
• Diabetes with vascular disease
• Headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35
• Undiagnosed abnormal genital bleeding
• Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past
• Liver tumors, benign or malignant, or liver disease
• Pregnancy

Trial design

1 participants in 1 patient group

Group 1

Description:

Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.

Treatment:

Drug: EV/DNG (Qlaira, BAY86-5027)